Related Experiment Videos
Toxic epidermal necrolysis associated with interleukin-2.
Angel A Segura Huerta1, Pablo Tordera, Ana C Cercós
1Medical Oncology Department, University Hospital La Fe, Valencia, Spain. segura_ang@gav.es
The Annals of Pharmacotherapy
|June 28, 2002
Summary
Metastatic renal cell carcinoma (MRCC) treatment with interleukin-2 (IL-2) can cause severe skin and blood toxicity. This rare, severe reaction highlights the need for careful patient selection and monitoring during IL-2 immunotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Metastatic renal cell carcinoma (MRCC) shows poor response to traditional chemotherapy.
- Interleukin-2 (IL-2) and interferon alfa are primary treatments for MRCC.
- Subcutaneous IL-2 is generally safe, with a low mortality rate.
Observation:
- A 67-year-old woman with metastatic cancer received IL-2 immunotherapy.
- Within 5 days, she developed toxic epidermal necrolysis and grade 4 pancytopenia.
- The patient experienced fatal hematologic toxicity and severe cutaneous reactions.
Findings:
- Cutaneous adverse effects of IL-2 are common but typically mild and reversible.
- Hematologic side effects are usually temporary, with pancytopenia being infrequent.
- The patient's severe cutaneous and hematologic toxicity is rarely reported.
Implications:
- IL-2 use in debilitated patients (performance status >2) requires individualized assessment.
- IL-2 therapy should be postponed if extensive radiotherapy is necessary.
- This case underscores the potential for severe, rare adverse events with IL-2 immunotherapy.